Jeff Greve

Jeff Greve is the current Scientific Advisor at Abalone Bio. Prior to this, they were the Chief Scientist at Cytokine Biology at Celgene from February 2017 to January 2018. Jeff was responsible for integrating Delinia into Celgene. Before that, they were the Founder and Chief Scientific Officer at Delinia from May 2014 to January 2017 where they developed novel Treg-selective IL-2 agonists for the treatment of Autoimmune Diseases. The company was acquired by Celgene in 2017 for $775M. Prior to that, they were the Vice President of Research at aTyr Pharma Inc from August 2011 to April 2013 where they were responsible for the discovery and development of a novel class of protein therapeutics for autoimmune and inflammatory diseases. Before that, they were the Executive Director of Exelixis Stem Cell Sciences from April 2005 to August 2011 where they were responsible for stem cell biology, Notch pathway therapeutics, protein therapeutics, and small molecule drug discovery. Jeff has also held positions as a Biotechnology Professional and Director of Research at Bayer Biotechnology from February 1991 to April 2004 and Senior Scientist at Molecular Therapeutics Inc from January 1986 to December 1991.

Jeff Greve graduated from The Johns Hopkins University with a BA in Biology. Jeff then went on to earn their PhD in Molecular Biology from Washington University in St. Louis. Finally, they completed a postdoc in Biological Chemistry at Harvard Medical School.